Key result
The amount of parenchymal fibronectin (OR 14.1; P<0.001), hypertension (OR 4.8; P=0.028), and HOMA-IR >8 (OR 1.9; P=0.004) independently predicted fibrosis progression in obese patients with NASH.
Why the study?
Do parenchymal fibronectin, HOMA-IR, and hypertension predict fibrosis progression in obese patients with NASH?
Cohort (n=271)
Do parenchymal fibronectin, HOMA-IR, and hypertension predict fibrosis progression in obese patients with NASH?
Odds Ratio: 14.1
p-value: p=<0.001
Parenchymal fibronectin, hypertension, and high HOMA-IR are independent predictors of fibrosis progression in obese patients with NASH.
No takes yet. Share an insight, caveat, or question.
May support fibrosis risk stratification in obese NASH; hypothesis-generating, requiring prospective validation.
Sorrentino et al. (2009) conducted a cohort in Nonalcoholic fatty liver disease (NAFLD) in obese patients (n=271). Parenchymal fibronectin (Fn), hypertension, and HOMA-IR >8 was evaluated on Fibrosis progression by at least one stage in the second liver biopsy (OR 14.1, p=<0.001). The amount of parenchymal fibronectin (OR 14.1; P<0.001), hypertension (OR 4.8; P=0.028), and HOMA-IR >8 (OR 1.9; P=0.004) independently predicted fibrosis progression in obese patients with NASH.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: